Preparation and in vitro/in vivo evaluation of dextran matrix tablets of budesonide in experimental ulcerative colitis in rats

Drug Delivery

Volumn 18, Issue 2, 2011, Pages 122-130

  Ahmadi, Fatemeh ^a   Varshosaz, Jaleh ^a   Emami, Jaber ^a   Tavakoli, Naser ^a   Minaiyan, Mohsen ^a   Mahzouni, Parvin ^a   Dorkoosh, Farid ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Acid induced colitis; Colon targeted delivery; Corticosteroid; Inflammation; Pathological assessment

Indexed keywords

ACETIC ACID; BUDESONIDE; CARBOXYMETHYLCELLULOSE; DEXTRAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG SOLUBILITY; DRUG SYNTHESIS; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MALE; MATRIX TABLET; MOLECULAR WEIGHT; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; TABLET HARDNESS; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; BUDESONIDE; CHEMISTRY, PHARMACEUTICAL; COLITIS, ULCERATIVE; COLON; DEXTRANS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; MALE; MOLECULAR WEIGHT; PHYSICAL PHENOMENA; POLYMERS; RATS; RATS, WISTAR; RECTUM; SOLUBILITY; TABLETS;

EID: 78650792101     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2010.520352     Document Type: Article

References (34)

1. Ahrabi, S.F., Madsen, G., Dyrstad, K., Sande, S.A., Graffner, C. (2000). Development of pectin matrix tablets for colonic delivery of model drug ropivacaine. Eur J Pharm Sci. 10:43-52.
2. Aslan, A.M., Temiz, M., Atik, E., Polat, G., Sahinler, N., Besirov, E., Aba, N., Parsak, C. (2007). Effectiveness of mesalamine and propolis in experimental colitis. Adv Ther. 24:1085-97.
3. Basan, H., Gumusderelioglu, M, Tevfik Orbey, M. (2007). Release characteristics of salmon calcitonin from dextran hydrogels for colon-specific delivery. Eur J Pharm Biopharm. 65;39-46.
4. Brunner, M., Ziegler, S., Di Stefano, A.F.D., Dehghanyar, P., Kletter, K., Tschurlovits, M., Villa, R., Bozzella, R., Celasco, G., Moro, L., Rusca, A., Dudczak, R., Muller, M. (2006). Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation. Br J Clin Pharmacol. 61:31-8.
5. Cooper, H.S., Murthy, S.N.S., Shah, R.S., Sedergran, D.J. (1993). Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 69:238-49.
6. Crcarevska, M.S., Dodov, M.G., Goracinova, K. (2008). Chitosan coated Ca-alginate microparticles loaded with budesonide for delivery to the inflamed colonic mucosa. Eur J Pharm Biopharm. 68:565-78.
7. Cui, N., Friend, D.R., Fedorak, R.N. (1994). A budesonide prodrug accelerates treatment of colitis in rats. Gut. 35:1439-46.
8. Dieleman, L.A., Palmen, M.J.H.J., Akol, H., Bloemena, E., Pena, A.S., Meuwissen, S.G.M., Van Ress, E.P. (1998). Chronic experimental colitis induced by dextransulfate sodium (DSS) is characterized by Th1 and Th2 Cytokines. Clin Exp Immuno. 114:385-911.
9. Edsbacker, S., Andersson, T., McKeage, K., Goa, K.L. (2004). Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease. Clin Pharmacokinet. 43:803-21.
10. Ei-Arini, S.K., Leuenberger, H. (1995). Modelling of drug release from polymer matrices: Effect of drug loading. Int J Pharm. 121:141-8.
11. El Medany, A., Mahgoub, A., Mustafa, A., Arafa, M., Morsi, M. (2005). The effects of selective cyclooxygenase-2 inhibitors, celecoxib and rofecoxib, on experimental colitis induced by acetic acid in rats. Eur J Pharmacol. 507:291-9.
12. Friend, D.R. (1998). Issues in oral administration of locally acting glucocorticosteroids for treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 12:591-603.
13. Friend, D.R. (2005). New oral delivery systems for treatment of inflammatory bowel disease. Adv Drug Del Rev. 57:247-65.
14. Gennaro, A. (2000). Remington: The science and practice of pharmacy. Easton, PA: Mack Publishing Company.
15. Gil, E.C., Colarte, A.I., Bataille, B., Pedraz, J.L., Rodriguez, F., Heinamaki, J. (2006). Development and optimization of a novel sustained-release dextran tablet formulation for propranolol hydrochloride. Int J Pharm. 317:32-9.
16. Gohel, M.C., Panchal, M.K. (2002). Novel use of similarity factors and sd for the development of diltiazem hcl modified-release tablets using a 3-2 factorial design. Drug Dev Ind Pharm. 28:77-87.
17. Gupta, M., Bhargava, H.N. (2006). Development and validation of a high-performance liquid chromatographic method for the analysis of budesonide. J Pharm Biomed Anal. 40:423-8.
18. Hovgaard, L., Brondsted, H. (1995). Dextran hydrogels for colon-specific drug delivery. J Contr Rel. 36:159-66.
19. Krishnaiah, Y.S., Satyanarayana, V., Dinesh, K.B., Karthikeyan, R.S. (2002). In vitro drug release studies on guar gum-based colon targeted oral drug delivery systems of 5-fluorouracil. Eur J Pharm Sci.16:185-92. (Pubitemid 34786453)
20. Krishnaiah, Y.S., Veer, R.P., Dinesh, K.B., Bhaskar, P. Satyanarayana, V. (2001). Development of colon targeted drug delivery systems for mebendazole. J Contr Re. 77:87-95.
21. Lee, J.S., Jung, Y.J., Doh, M.J., Kim, Y.M. (2001). Synthesis and properties of dextran-nalidixic acid ester as a colon-specific prodrug of nalidixic acid. Drug Dev Ind Pharm. 27:331-6.
22. McLeod, A.D., Friend, D.R., Tozer, T.N. (1993). Synthesis and chemical stability of glucocorticoid-dextran esters: Potential prodrugs for colon-specific delivery. Int J Pharm. 92:105-14.
23. Mehvar, R. (2000). Dextrans for targeted and sustained delivery of therapeutic and imaging agents. J Contr Rel. 69:1-25.
24. Minko, T. (2004). Drug targeting to the colon with lectins and neoglycoconjugates. Adv Drug Del Rev. 56:491-509.
25. Paiva, L.A.F., Gurgel, L.A. (2004). Protective effect of Copaifera langsdorffii oleo-resin against acetic acid-induced colitis in rats. J Ethnopharmacol. 93:51-6.
26. Reddy, K.R., Mutalik, S, Reddy, S. (2003). Once-daily sustained-release matrix tablets of nicorandil: Formulation and in vitro evaluation. AAPS PharmSciTech. 4:Article 61.
27. Rodriguez, M., Antunez, J.A., Taboada, C., Seijo, B., Torres, D. (2001). Colon-specific delivery of budesonide from microencapsulated cellulosic cores: Evaluation of the efficacy against colonic inflammation in rats. J Pharm Pharmacol. 53:1207-15.
28. Sharon, P., Stenson, W.P. (1995). Metabolism of arachidonic acid in acetic colitis in rats: Similarity to human inflammatory bowel disease. Gastroenterol. 88:55-63.
29. Shimono, N., Takatori, T., Ueda, M., Mori, M., Higashi, Y., Nakamura, Y. (2002). Chitosan dispersed system for colon-specific drug delivery. Int J Pharm. 245:45-54.
30. Shyale, S., Chowdhary, K.P.R., Krishnaiah, Y.S.R. (2005). Development of colon-targeted albendazole-b-cyclodextrin-complex drug delivery systems. Drug Dev Res. 65:76-83.
31. The United States Pharmacopeia. (2007). Rockville, MD: United States Pharmacopeial Convention Inc.
32. Varshosaz, J., Emami, J., Tavakoli, N., Fassihi, A., Minaiyan, M., Ahmadi, F., Dorkoosh, F. (2009). Synthesis and evaluation of dextran-budesonide conjugates as colon specific prodrugs for treatment of ulcerative colitis. Int J Pharm. 365:69-76.
33. Williams, K.L., Randall Fuller, C., Dieleman, L.A., DaCosta, C.M., Haldeman, K.M., Balfour Sartor, R., Kay Lund, P. (2001). Enhanced survival and mucosal repair after dextran sodium sulfate- induced colitis in transgenic mice that overexpress growth hormone. Gastroenterol. 120:925-37.
34. Yehia, S.A., Elshafeey, AH., Sayed, I., Shehata, A.H. (2009). Optimization of budesonide compression-coated tablets for colonic delivery. AAPS PharmSciTech. 10:147-57.